Analysts expect that InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) will announce ($0.16) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for InVivo Therapeutics’ earnings. InVivo Therapeutics reported earnings of ($0.21) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 23.8%. The firm is expected to announce its next earnings report on Friday, March 9th.
According to Zacks, analysts expect that InVivo Therapeutics will report full-year earnings of ($0.81) per share for the current year, with EPS estimates ranging from ($0.83) to ($0.79). For the next financial year, analysts anticipate that the business will report earnings of ($0.74) per share, with EPS estimates ranging from ($0.87) to ($0.61). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for InVivo Therapeutics.
InVivo Therapeutics (NASDAQ:NVIV) last released its quarterly earnings results on Monday, October 30th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06).
Separately, ValuEngine cut InVivo Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. LMR Partners LLP bought a new position in InVivo Therapeutics during the 2nd quarter worth approximately $159,000. Blair William & Co. IL bought a new position in InVivo Therapeutics during the 2nd quarter worth approximately $159,000. Goldman Sachs Group Inc. grew its position in InVivo Therapeutics by 144.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 167,318 shares of the biotechnology company’s stock worth $452,000 after acquiring an additional 98,879 shares during the last quarter. Susquehanna International Group LLP bought a new position in InVivo Therapeutics during the 2nd quarter worth approximately $434,000. Finally, Legal & General Group Plc grew its position in InVivo Therapeutics by 4,427.9% during the 2nd quarter. Legal & General Group Plc now owns 503,407 shares of the biotechnology company’s stock worth $1,359,000 after acquiring an additional 492,289 shares during the last quarter. 12.83% of the stock is currently owned by institutional investors.
InVivo Therapeutics (NASDAQ NVIV) opened at $1.17 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 5.06 and a current ratio of 5.06. InVivo Therapeutics has a 1-year low of $1.10 and a 1-year high of $5.07.
InVivo Therapeutics Company Profile
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for InVivo Therapeutics Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics Holdings Corp. and related companies with MarketBeat.com's FREE daily email newsletter.